BJDX
Bluejay Diagnostics, Inc.
- PER (TTM)
- -
- PER (Forward)
- -5.38
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 0.43
- 시가총액
- 1.78M
- 배당수익률
- -
- 베타
- -
- 1개월 수익률
- -4.97%
- 3개월 수익률
- -49.26%
- 6개월 수익률
- -75.14%
- 1년 수익률
- -75.03%
- 2년 수익률
- -
- 5일 평균거래량
- 17860
- 60일 평균거래량
- 189472
- 1년 평균거래량
- 366434
- 5d/60d 거래량 비율
- 0.09×
- 60d/1y 거래량 비율
- 0.52×
- 변동성(60일, 연환산)
- 74.32%
- BB 스퀴즈 스코어
- 0.38
- SMA50 비율
- 0.90
- SMA200 비율
- 0.38
- RSI (14)
- 38
- 20일 수렴도
- 0.04
- 52주 최고
- 14.00
- 52주 최저
- 1.72
- 고점 대비
- -87.71%
- 저점 대비
- 0.00%
펀더멘털 갱신: 2026-05-10T07:59:48+00:00 · 시세 갱신: 2026-05-10T06:12:53+00:00
회사 정보
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.